Interestingly, among 175 AML cases presenting with intermediate-risk cytogenetics, 3-y EFS and OS for patients with low and high CD206 expression were 47% vs. 25% and 56% vs. 32%, respectively (p < 0.001) [43]. Here, MRC1 is linked to acute myeloid leukemia.